Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 14/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31078266 | 0.92 | — | — | |
| SCHEMBL23270563 | 0.91 | NT5E (0.36) | NT5E | |
| SCHEMBL31078220 | 0.91 | NT5E (0.32) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL23270470 | 0.90 | NT5E (0.33) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL23270606 | 0.90 | NT5E (0.32) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL23752746 | 0.89 | NT5E (0.33) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL31078437 | 0.89 | NT5E (0.36) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL23270580 | 0.87 | NT5E (0.33) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL31622317 | 0.87 | NT5E (0.33) | NT5EADORA1ADORA3ADORA2A | |
| SCHEMBL31078424 | 0.84 | NT5E (0.43) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | PELOTON THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3810109-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING CD73 | PELOTON THERAPEUTICS INC (US) | 2024-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA1 35/4885ADORA3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.